Burzynski Research Institute (Burzynski Research Institute) Cash-to-Debt : No Debt ⁽¹⁾ (As of Nov. 2023)

View and export this data going back to . Start your Free Trial

What is Burzynski Research Institute Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Burzynski Research Institute's cash to debt ratio for the quarter that ended in Nov. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Burzynski Research Institute could pay off its debt using the cash in hand for the quarter that ended in Nov. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Burzynski Research Institute's Cash-to-Debt or its related term are showing as below:

BZYR' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, Burzynski Research Institute's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

BZYR's Cash-to-Debt is ranked better than
99.8% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs BZYR: No Debt

Burzynski Research Institute Cash-to-Debt Historical Data

The historical data trend for Burzynski Research Institute's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Burzynski Research Institute Cash-to-Debt Chart

Burzynski Research Institute Annual Data

Trend

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Feb23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

N/A

No Debt

Burzynski Research Institute Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	N/A	No Debt	No Debt

Competitive Comparison of Burzynski Research Institute's Cash-to-Debt

For the Biotechnology subindustry, Burzynski Research Institute's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burzynski Research Institute's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Burzynski Research Institute's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Burzynski Research Institute's Cash-to-Debt falls into.

Burzynski Research Institute Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Burzynski Research Institute's Cash to Debt Ratio for the fiscal year that ended in Feb. 2023 is calculated as:

Burzynski Research Institute had no debt ⁽¹⁾.

Burzynski Research Institute's Cash to Debt Ratio for the quarter that ended in Nov. 2023 is calculated as:

Burzynski Research Institute had no debt ⁽¹⁾.

Burzynski Research Institute (OTCPK:BZYR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Burzynski Research Institute Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Burzynski Research Institute's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Burzynski Research Institute (Burzynski Research Institute) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Burzynski Research Institute Inc (OTCPK:BZYR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

9432 Katy Freeway, Houston, TX, USA, 77055

Website

http://www.burzynskiresearch.com

Burzynski Research Institute Inc engages in the research, production, marketing, promotion, and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are used in the treatment of human cancer. Its pipeline development programs of the company include clinical trials for the treatment of a wide variety of cancers using only a combination of Antineoplastons A10 and AS2-1.

Executives

Monika Szopa-paszkowiak	director	9432 KATY FWY #200, HOUSTON TX 77055
Frederick Richard Schiff	director	9432 KATY FREEWAY, HOUSTON TX 77055
Barbara Burzynski	director, 10 percent owner	9432 KATY FREEWAY, HOUSTON TX 77055
Carlton Hazlewood	director	9432 KATY FREEWAY, HOUSTON TX 77055
Patryk Goscianski	officer: Secretary and Treasurer	9432 KATY FREEWAY, HOUSTON TX 77055
Gregory Burzynski	director	9432 KATY FREEWAY, HOUSTON TX 77055
Tomasz Janicki	officer: VP of Clinical Trials	9432 KATY FREEWAY, HOUSTON TX 77055
Michael Driscoll	director	9432 KATY FREEWAY, HOUSTON TX 77055
Stanislaw Burzynski	director, 10 percent owner, officer: President	9432 KATY FREEWAY, HOUSTON TX 77055
Dudley Reece Anderson	officer: Chief Financial Officer	9432 OLD KATY RD., SUITE 200, HOUSTON TX 77055

Burzynski Research Institute (Burzynski Research Institute) Headlines

No Headlines

Burzynski Research Institute (Burzynski Research Institute) Cash-to-Debt : No Debt (1) (As of Nov. 2023)